RYTM Share Price Performance
US$113.76
60.77 (114.68%)
3.2% undervalued intrinsic discount
US$117.57
Fair Value
Price US$113.76
AnalystConsensusTarget US$117.57
Fair ValueUS$117.57
Share PriceUS$113.76
3.2% undervalued intrinsic discount
Rhythm Pharmaceuticals, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 6 Fair Values set on narratives written by author
RYTM Community Narratives
AN
Fair Value US$117.57 3.2% undervalued intrinsic discount
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Analysts Boost Rhythm Pharmaceuticals Outlook Amid Setmelanotide Progress and Revised Valuation Metrics
Key Takeaways Expansion into new indications and age groups, alongside global diagnostic trends, positions Rhythm for sustained patient base and revenue growth. Strong intellectual property and regulatory advantages ensure high margins, pricing power, and long-term resilience against competitive threats.Read more
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$117.57
3.2% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
68.19% p.a.
Profit Margin
31.48%
Future PE
49.63x
Share price in 2028
US$142.79
Snowflake Analysis
Rhythm Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 04, 2025
- -2.84
- 89.25%
- -120.57%
- 82.2%
About RYTM
- Founded
- 2008
- Employees
- 283
- CEO
- WebsiteView website
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
